Quintiles Library

Harnessing Vital Data Image
Featured White Paper

Harnessing vital data to inform an optimal market access strategy in the UK
Market access now demands closer collaboration between biopharma, payers and providers. In a climate where ongoing reimbursement of a drug relies on biopharma’s ability to demonstrate how it delivers value to the entire healthcare system, partnership working is essential. Outcomes audits should be seen as one of the most important tools available to biopharma. They deliver detailed action plans to both biopharma and the NHS, proposing improvements to the care pathway...
Show Filters
Brochure
The emerging markets of Asia Pacific offer tremendous potential for clinical research, but differences in patient populations, infrastructure and the number of available investigators make completing studies on time and within internationally recognized quality standards a complex undertaking. Quintiles offers the experience, expertise and strategy that can accelerate site identification and recruitment, critical components that bring greater efficiencies to your...
Read more
Expert
Integrated Channel Management offers an approach to combine e-solutions and traditional channels into a customized and cost-effective and optimized communications mix. Read more on what Peter Dussias has to say on this approach. Authors: Peter Dussias, Sr. Director Integrated Channel Management, North...
Read More
Fact Sheet
The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are increasingly proactive in ensuring that the benefit-risk balance of a medicine is positive throughout the entire life cycle of a medicine for all patients in the target population. Both the EMA and the FDA are making transparency a priority; proactively seeking the viewpoints of patients and other stakeholders; encouraging advances in safety science; asking for acknowledgment of the populations excluded from clinical trials; striving for optimum safety integration into the healthcare system; and assessing a medication’s value by examining its benefit-risk trade-offs in populations and sub-populations. This shift in approach and demand for more real-world data provides challenges and opportunities in...
Read More
Brochure
Maximize your commercial success by knowing how to navigate the UK healthcare system. Starting with identification of the key stakeholders involved in drug adoption, getting access to them to engage them in a dialog about your new therapy, and also get their views on potential patient-centric programs that could help achieve better patient outcomes in their communities. Market Access in the UK is a journey that involves a variety of steps. Read our brochure to learn...
Read More
Press Release
SEOUL – January 23, 2015 – Quintiles today announced the launch of a handbook to guide physicians in the conduct of investigator initiated clinical trials. Top clinical researchers from academia and industry across Asia-Pacific joined Quintiles’ experts in contributing to and editing the handbook, which Quintiles sponsored as part of its ongoing efforts to enhance clinical research globally and create a healthier world. Availability of the handbook, “Investigator Initiated Trials Made Easy,” was announced at a press conference held at Seoul National University Hospital in South Korea. “Investigator initiated, patient-focused clinical trials play a vital role in improving and expanding patient care in the real world,” said Dr. Stephanie Tan, MBBS, Quintiles Site and Patient Network, Asia,...
Read More
White Paper
Quintiles has developed a two-part global investigation in more than 100 countries to confirm “what works where” for patient recruitment and retention tools and techniques. Authors: Chris Frega, Senior Director, Integrated Site Services & Stacy Whaley, Associate Director, Patient & Site...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – January 19, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its fourth-quarter 2014 financial results Thursday, February 12, 2015 prior to its quarterly earnings call at 8:00 a.m. EST. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 484-7367 in the United States or +1 (631) 259-7541 outside the United States, approximately 15 minutes before the scheduled start of the call. An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EST on Thursday, February 12th. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – January 15, 2015 – Expression Analysis (EA), a Quintiles company, today announced the winners of a grant program that provides scientists with leading-edge products and services to advance genomics research. In this sixth year of the program, EA and co-sponsor, Illumina, awarded two fully funded research grants to investigate genomic data locked within Formalin-Fixed, Paraffin Embedded (FFPE) tumor samples – a largely untapped data pool that can help enhance researchers’ understanding of cancer biology.  After a rigorous review of nearly 700 submissions by a distinguished panel of judges, two researchers were selected to receive grants. The recipients include: Professor Anne Bowcock, Ph.D., chair of Cancer Genomics at Imperial College London, who will...
Read More
White Paper
Biomarkers hold promise in the diagnosis, prognosis and therapeutic stratification of hematopoietic malignancies. These heterogeneous diseases – including multiple myeloma, lymphomas and leukemias – are frequently characterized cytogenetically with diagnoses supported by genetic, immunohistochemical and flow cytometric analyses. Biomarkers offer the hope of early detection as well as tracking disease progression and recurrence. Early detection may help improvesurvival, as it could help identify individuals most at risk for disease development, distinguish aggressive from indolent disease, and track disease progression. In therapeutic stratification, biomarkers potentially allow for patient-specific selection of agents that are likely to be effective and not cause unnecessary toxicity....
Explore here
White Paper
Autism spectrum disorder (ASD) – a group of conditions characterized by deficits in social interactions and communication skills, as well as the presence of stereotypic and repetitive behaviors – is estimated to affect 1% of the global population.[i] A recent review of published data concluded that the median of prevalence estimates of autism spectrum disorder worldwide was 62/10,000.[ii] ASD is almost five times more common among boys (1 in 54) than girls (1 in 252), according to the US Centers for Disease Control and Prevention.[iii] ASD commonly co-occurs with other developmental, psychiatric, neurologic, chromosomal, and genetic diagnoses. The co-occurrence of one or more non-ASD developmental diagnoses is 83%, and the co-occurrence of one or more psychiatric diagnoses is 10%.[iv]...
Explore here
Media Coverage
As featured in the December 2014 issue of Pharmaceutical Field, John Pinching talks to Quintiles' Tanya Byron about how E-detailing is changing perceptions and providing an effective sales platform for engaging with...
Read More
White Paper
The biopharmaceutical industry is currently facing a number of macro-environmental factors, which underscore its need to think of itself not as a developer of singular products, but as a critical part of an interoperable system. This fundamental shift must include a strategic approach for engaging with an increasingly informed and connected patient population. The amount of medical information now available to patients online is truly remarkable. Coupled with a decrease in the amount of time physicians can actually spend with their patients, today’s health care consumers are savvy, engaged and have a strong desire to learn as much as they can about their diseases. By not directly engaging with patients, biopharmaceutical companies are missing an enormous opportunity to reduce the time...
Explore here
White Paper
Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society estimates that in 2013, about 238,590 new cases of prostate cancer will be diagnosed, and around 29,720 men will die of prostate cancer; some one in six men will be diagnosed with prostate cancer during his lifetime. Due to its widespread incidence and unmet medical need, prostate cancer is the target of a significant proportion of clinical research and ranks fifth in terms of number of Development Programs in phase I to phase III, after breast cancer, leukemia, colorectal cancer and lymphoma.Prostate cancer faces almost all the main challenges typically found in oncology clinical development, including:Operational: The prostate cancer patient pathway has always been a critical...
Explore here
White Paper
The current biopharma drug development paradigm, including an organizational structure centered around project teams, is not well-constituted to embody design best practices even though design of clinical trials is at the heart of the drug development endeavor. Teams tend to be formed on the basis of technical or therapeutic expertise, not on the basis of well-honed design skills. Furthermore, teams tend not to be incentivized to foster open approaches to design or to use structured design methodologies that lead to high quality and performance.As a result, there is great variability in the quality of the programs and trial designs produced by project teams. This results in less efficient clinical trial execution or failed outcomes. A more systematic approach to design — grounded in best...
Explore here
Fact Sheet
With a reputation for world-class healthcare and a highly developed infrastructure, Singapore offers the opportunity to create a longstanding platform for drug development and market launch. With Quintiles as your local partner, you can have the right resources, expertise and relationships in place to turn your clinical and commercial goals into reality. Whether Singapore is your sole market of interest or simply part of a larger Asia Pacific strategy, Quintiles can offer a fully integrated approach that connects insights with superior delivery. Contact us today for help meeting your development and market access...
Read More
Fact Sheet
Quintiles’ Diabetes Center of Excellence couples our therapeutic expertise with a proven ability to recruit patients across the globe to help you realize the full potential of your drug development investment....
Read more
Fact Sheet
For one of the most mature markets in the world, Japan continues to offer huge opportunities for growth. It is the largest pharmaceutical market in the Asia Pacific region and second only to North America worldwide. With government healthcare reforms spurring innovation, Japan equals the promise of emerging countries without the risk. Quintiles’ integrated teams, backed by our global standards, processes and technology, provide the expertise you need to confidently develop and market therapies in Japan. Whether you’re looking to enter Japan only or the larger Asia Pacific market, trust Quintiles to help deliver on your globalization...
Read more
White Paper
Organizations and entrepreneurs have tapped into the power of crowds for many generations. With the pervasiveness of social platforms have come new, simpler, and more economical methods to draw upon the capabilities of a truly global crowd. In this paper we present three case studies in which crowdsourcing was used in the healthcare industry. From these scenarios we present guidance and considerations in successfully planning and conducting crowdsourcing programs....
Explore here
Fact Sheet
Pharmaceutical companies are crossing borders around the globe, leading many to seek the best markets for expansion. Japan is often at the top of that list. As the second largest pharma market in the world, Japan offers advantages from universal healthcare coverage to extended patent cycles to government support of innovation. Entering the Japanese market, however, requires a clear understanding of the unique regulatory requirements and advantages of conducting clinical development in Japan. Quintiles’ local In-Country Clinical Caretaker (ICCC) team can help you directly conduct clinical trials in Japan as the drug sponsor.  It’s the option that allows you to retain control and minimize...
Read more
White Paper
How is next generation sequencing (NGS) transforming oncology clinical development and treatments for cancer?  Read this recent whitepaper to learn how.  The overall goal in the era of emerging precision is to develop cancer medications that attack the right target, or targets, in the right disease, in the right patient, at the right dose to obtain the desired outcome.  Several targeted therapies have successfully been developed and the pipeline of additional precision medicines looks promising.  But how can the drug development community better capitalize on sophisticated genomics-based tools available to help transform clinical development and cancer care in the coming decade? This paper investigates fundamentals and key considerations to integrating NGS in the clinical development of...
Explore More